Bhutan
Tuberculosis profile
Population  2013 <1 million
Estimates of TB burden * 2013 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.088 (0.052–0.18) 12 (6.9–23)
Mortality (HIV+TB only) 0 (–) 0 (–)
Prevalence  (includes HIV+TB) 1.5 (0.5–3) 196 (67–393)
Incidence  (includes HIV+TB) 1.3 (1.2–1.4) 169 (156–190)
Incidence (HIV+TB only) <0.01 (<0.01–<0.01) 0.15 (0.14–0.17)
Case detection, all forms (%) 85 (76–92)    
Estimates of MDR-TB burden * 2013   New   Retreatment
% of TB cases with MDR-TB 2.2 (1.8–2.7) 35 (21–52)
MDR-TB cases among notified pulmonary
TB cases
12 (10–15) 35 (20–51)
TB case notifications 2013 New ** Relapse
Pulmonary, bacteriologically confirmed 425   64
Pulmonary, clinically diagnosed 120   0
Extrapulmonary 471   0
       
Total new and relapse 1 080    
Previously treated, excluding relapses 35    
Total cases notified 1 115    
Among 1 071 new and relapse cases:
57 (5%) cases aged under 15 years; male:female ratio: 1.0
Reported cases of RR-/MDR-TB 2013 New Retreatment Total **
Cases tested for RR-/MDR-TB 188 (44%) 29 (29%) 257
Laboratory-confirmed RR-/MDR-TB cases     65
Patients started on MDR-TB treatment     49
TB/HIV 2013 Number (%)
TB patients with known HIV status 1 115 (100)
HIV-positive TB patients 1 (<1)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 0 (0)
HIV-positive TB patients on antiretroviral therapy (ART) 1 (100)
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Treatment success rate (%)
New and relapse cases registered in 2012 92
Previously treated cases, excluding relapse, registered in 2012 35
HIV-positive TB cases, all types, registered in 2012  
RR-/MDR-TB cases started on second-line treatment in 2011 86
XDR-TB cases started on second-line treatment in 2011  
Laboratories 2013  
Smear (per 100 000 population) 4.6
Culture (per 5 million population) 6.6
Drug susceptibility testing (per 5 million population) 6.6
Sites performing Xpert MTB/RIF  
Is second-line drug susceptibility testing available? Yes, in and outside
country
Financing TB control 2014  
National TB programme budget (US$ millions) <1
% Funded domestically 18%
% Funded internationally 82%
% Unfunded 0%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2015-08-02 Data: www.who.int/tb/data